The Worst Mistake Trillium Investors Can Make Right Now
In his book One Up on Wall Street, Peter Lynch says that "selling winners and holding your losers is like cutting the flowers and watering the weeds." That's great advice in some circumstances, but following it might be the worst thing shareholders of Trillium Therapeutics (NASDAQ: TRIL) could do right now.
Image source: Getty Images
Trillium shares climbed from $0.30 per share in November 2019 to $20 a year later after the company hired a new CEO and focused research on two promising molecules that effectively block the ability of cancer cells to hide from the immune system.
Source Fool.com
